Cardiovascular risk factor treatment targets and renal complications in high risk vascular patients: A cohort study

BMC Cardiovascular Disorders

Volumn 11, Issue , 2011, Pages

  Selvarajah, Sharmini ^a,b   vD Graaf, Yolanda ^b   Visseren, Frank L J ^b   Bots, Michiel L ^b  

^a HOSPITAL KUALA LUMPUR   (Malaysia)

^b UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOTENSIN RECEPTOR ANTAGONIST; ANTICOAGULANT AGENT; ANTILIPEMIC AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; LOW DENSITY LIPOPROTEIN CHOLESTEROL;

ADULT; AGE DISTRIBUTION; AGED; ALBUMINURIA; ARTICLE; ATHEROSCLEROSIS; BLOOD PRESSURE REGULATION; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CHOLESTEROL BLOOD LEVEL; CLINICAL PRACTICE; COHORT ANALYSIS; CONTROLLED STUDY; DIABETES MELLITUS; DIASTOLIC BLOOD PRESSURE; DRUG TARGETING; HAZARD RATIO; HIGH RISK PATIENT; HUMAN; HYPERTENSION; INCIDENCE; KIDNEY DISEASE; KIDNEY FAILURE; MAJOR CLINICAL STUDY; MALE; NETHERLANDS; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PROSPECTIVE STUDY; RISK REDUCTION; SEX RATIO; SYSTOLIC BLOOD PRESSURE; BLOOD; BLOOD PRESSURE; COMPARATIVE STUDY; FEMALE; FOLLOW UP; MIDDLE AGED; PHYSIOLOGY; RISK FACTOR; TREATMENT OUTCOME;

AGED; BLOOD PRESSURE; CARDIOVASCULAR DISEASES; COHORT STUDIES; DIABETES MELLITUS; FEMALE; FOLLOW-UP STUDIES; HUMANS; HYPERTENSION; KIDNEY DISEASES; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; RISK FACTORS; TREATMENT OUTCOME;

EID: 79959820362     PISSN: None     EISSN: 14712261     Source Type: Journal    
DOI: 10.1186/1471-2261-11-40     Document Type: Article

References (39)

1. Rydén L, Standl E, Bartnik M, Van den Berghe G, Betteridge J, de Boer M-J, Cosentino F, Jönsson B, Laakso M, Malmberg K, et al. Guidelines on diabetes, pre-diabetes, and cardiovascular diseases: executive summary. European Heart Journal 2007, 28:88-136.
2. Mancia G, Co C, De Backer G, Dominiczak A, Cifkova R, Fagard R, Germano G, Grassi G, Heagerty A, et al. Authors/Task Force M 2007 ESH-ESC Practice Guidelines for the Management of Arterial Hypertension: ESH-ESC Task Force on the Management of Arterial Hypertension. Journal of Hypertension 2007, 25:1751-1762. 10.1097/HJH.0b013e3282f0580f, 17762635, Authors/Task Force M.
3. Smulders Y, Burgers J, Scheltens T, van Hout B, Wiersma T, Simoons M. Clinical practice guideline for cardiovascular risk management in the Netherlands. The Netherlands Journal of Medicine 2008, 66:169-174.
4. Safian RD, Textor SC. Renal-Artery Stenosis. New England Journal of Medicine 2001, 344:431-442. 10.1056/NEJM200102083440607, 11172181.
5. El-Nahas AM, Tamimi N. The progression of chronic renal failure: a harmful quartet. QJM 1999, 92:421-424. 10.1093/qjmed/92.8.421, 10627857.
6. Kanda T, Wakino S, Hayashi K, Plutzky J. Cardiovascular Disease, Chronic Kidney Disease, and Type 2 Diabetes Mellitus: Proceeding with Caution at a Dangerous Intersection. Journal of the American Society of Nephrology 2008, 19:4-7. 10.1681/ASN.2007111182, 18178795.
7. Perneger TV, Brancati FL, Whelton PK, Klag MJ. End-Stage Renal Disease Attributable to Diabetes Mellitus. Annals of Internal Medicine 1994, 121:912-918.
8. Valderrabano F, Gomez-Campdera F, Jones EHP. Hypertension as cause of end-stage renal disease: Lessons from international registries. Kidney International 1998, 54:S60-S66.
9. McClellan WM, Flanders WD. Risk Factors for Progressive Chronic Kidney Disease. Journal of the American Society of Nephrology 2003, 14:S65-70. 10.1097/01.ASN.0000070147.10399.9E, 12819305.
10. Group TEIS Geographic, ethnic, age-related and temporal variation in the incidence of end-stage renal disease in Europe, Canada and the Asia-Pacific region, 1998-2002. Nephrology Dialysis Transplantation 2006, 21:2178-2183. Group TEIS.
11. Fleming DM, Schellevis FG, Van Casteren V. The prevalence of known diabetes in eight European countries. The European Journal of Public Health 2004, 14:10-14.
12. Wolf-Maier K, Cooper RS, Banegas JR, Giampaoli S, Hense H-W, Joffres M, Kastarinen M, Poulter N, Primatesta P, Rodriguez-Artalejo F, et al. Hypertension Prevalence and Blood Pressure Levels in 6 European Countries, Canada, and the United States. The Journal of the American Medical Association 2003, 289:2363-2369.
13. Pugsley D. Racial and ethnic disparities in renal disease. Kidney International 2005, 68:1364-1365. 10.1111/j.1523-1755.2005.00545.x, 16105072.
14. Missouris CG, Barley J, Jeffery S, Carter ND, Singer DRJ, MacGregor GA. Genetic risk for renal artery stenosis: Association with deletion polymorphism in angiotensin 1-converting enzyme gene. Kidney International 1996, 49:534-537. 10.1038/ki.1996.76, 8821841.
15. Rimmer JM, Gennari FJ. Atherosclerotic Renovascular Disease and Progressive Renal Failure. Annals of Internal Medicine 1993, 118:712-719.
16. Brinkman JW, Bakker SJL, Gansevoort RT, Hillege HL, Kema IP, Gans ROB, de Jong PE, de Zeeuw D. Which method for quantifying urinary albumin excretion gives what outcome? A comparison of immunonephelometry with HPLC. Kidney International 2004, 66:S69-S75.
17. Simons PCG, Algra A, van de Laak MF, Grobbee DE, van der Graaf Y. Second Manifestations of ARTerial disease (SMART) study: Rationale and design. European Journal of Epidemiology 1999, 15:773-781. 10.1023/A:1007621514757, 10608355.
18. Graham I, Atar D, Borch-Johnsen K, Boysen G, Burell G, Cifkova R, Dallongeville J, De Backer G, Ebrahim S, Gjelsvik B, et al. European guidelines on cardiovascular disease prevention in clinical practice: executive summary. European Heart Journal 2007, 28:2375-2414.
19. Maione A, Navaneethan SD, Graziano G, Mitchell R, Johnson D, Mann JFE, Gao P, Craig JC, Tognoni G, Perkovic V, et al. Angiotensin-converting enzyme inhibitors, angiotensin receptor blockers and combined therapy in patients with micro- and macroalbuminuria and other cardiovascular risk factors: a systematic review of randomized controlled trials. Nephrology Dialysis Transplantation 2011,
20. Ruilope L, Izzo J, Haller H, Waeber B, Oparil S, Weber M, Bakris G, Sowers J. Prevention of Microalbuminuria in Patients With Type 2 Diabetes: What Do We Know?. The Journal of Clinical Hypertension 2010, 12:422-430. 10.1111/j.1751-7176.2010.00289.x, 20591087.
21. Eijkelkamp WBA, Zhang Z, Remuzzi G, Parving H-H, Cooper ME, Keane WF, Shahinfar S, Gleim GW, Weir MR, Brenner BM, et al. Albuminuria Is a Target for Renoprotective Therapy Independent from Blood Pressure in Patients with Type 2 Diabetic Nephropathy: Post Hoc Analysis from the Reduction of Endpoints in NIDDM with the Angiotensin II Antagonist Losartan (RENAAL) Trial. Journal of the American Society of Nephrology 2007, 18:1540-1546. 10.1681/ASN.2006050445, 17409317.
22. Haller H, Ito S, Izzo JL, Januszewicz A, Katayama S, Menne J, Mimran A, Rabelink TJ, Ritz E, Ruilope LM, et al. Olmesartan for the Delay or Prevention of Microalbuminuria in Type 2 Diabetes. New England Journal of Medicine 2011, 364:907-917. 10.1056/NEJMoa1007994, 21388309.
23. Tong S, Lu Y. Identification of Confounders in the Assessment of the Relationship between Lead Exposure and Child Development. Annals of Epidemiology 2001, 11:38-45. 10.1016/S1047-2797(00)00176-9, 11164118.
24. Benetos A, Thomas F, Bean K, Gautier S, Smulyan H, Guize L. Prognostic Value of Systolic and Diastolic Blood Pressure in Treated Hypertensive Men. Archives of Internal Medicine 2002, 162:577-581. 10.1001/archinte.162.5.577, 11871926.
25. Sirtori CR, Fumagalli R. LDL-cholesterol lowering or HDL-cholesterol raising for cardiovascular prevention: A lesson from cholesterol turnover studies and others. Atherosclerosis 2006, 186:1-11. 10.1016/j.atherosclerosis.2005.10.024, 16310198.
26. Chan JC, So W-Y, Yeung C-Y, Ko GT, Lau I-T, Tsang M-W, Lau K-P, Siu S-C, Li JK, Yeung VT, et al. Effects of Structured Versus Usual Care on Renal Endpoint in Type 2 Diabetes: The SURE Study. Diabetes Care 2009, 32:977-982. 10.2337/dc08-1908, 2681013, 19460913.
27. Vlahakos DV, Marathias KP, Madias NE. The Role of the Renin-Angiotensin System in the Regulation of Erythropoiesis. American Journal of Kidney Diseases 2010, 56:558-565. 10.1053/j.ajkd.2009.12.042, 20400218.
28. Kong APS, Yang X, Ko GTC, So W-Y, Chan W-B, Ma RCW, Ng VWS, Chow C-C, Cockram CS, Tong PCY, et al. Effects of Treatment Targets on Subsequent Cardiovascular Events in Chinese Patients With Type 2 Diabetes. Diabetes Care 2007, 30:953-959. 10.2337/dc06-2443, 17259475.
29. Cederholm J, Nilsson PM, Anderberg C-P, Fröberg L, Petersson U. Blood pressure and other cardiovascular risk factors among treated hypertensives in Swedish primary health care. Scandinavian Journal of Primary Health Care 2002, 20:224-229. 10.1080/028134302321004881, 12564574.
30. Kristianson K, Fyhrquist F, Devereux RB, Kjeldsen SE, Lindholm LH, Lyle PA, Nieminen MS, Snapinn SM. An analysis of cholesterol control and statin use in the losartan intervention for endpoint reduction in hypertension study. Clinical Therapeutics 2003, 25:1186-1199. 10.1016/S0149-2918(03)80075-9, 12809965.
31. MacDonald TM, Morant SV, Mozaffari E. Drug treatment discontinuation and achievement of target blood pressure and cholesterol in United Kingdom primary care. Current Medical Research and Opinion 2007, 23:2765-2774. 10.1185/030079907X233124, 17919356.
32. Vlek ALM, van der Graaf Y, Braam B, Moll FL, Nathoe HM, Visseren FLJ. Blood Pressure and Decline in Kidney Function in Patients With Atherosclerotic Vascular Disease: A Cohort Study. American Journal of Kidney Diseases 2009, 54:820-829. 10.1053/j.ajkd.2009.07.007, 19733947.
33. Laverman GD, Andersen S, Rossing P, Navis G, de Zeeuw D, Parving H-H. Renoprotection with and without blood pressure reduction. Kidney International 2005, 67:S54-S59.
34. Adler AI, Stevens RJ, Manley SE, Bilous RW, Cull CA, Holman RR. Development and progression of nephropathy in type 2 diabetes: The United Kingdom Prospective Diabetes Study (UKPDS 64). Kidney International 2003, 63:225-232. 10.1046/j.1523-1755.2003.00712.x, 12472787.
35. Radbill B, Murphy B, LeRoith D. Rationale and Strategies for Early Detection and Management of Diabetic Kidney Disease. Mayo Clinic Proceedings 2008, 83:1373-1381. 10.4065/83.12.1373, 19046557.
36. Broekroelofs J, Stegeman CA, Navis GJ, de Haan J, van der Bij W, de Boer WJ, de Zeeuw D, de Jong PE. Creatinine-based estimation of rate of long term renal function loss in lung transplant recipients. Which method is preferable?. The Journal of Heart and Lung Transplantation 2000, 19:256-262. 10.1016/S1053-2498(99)00133-3, 10713250.
37. Gera M, Slezak JM, Rule AD, Larson TS, Stegall MD, Cosio FG. Assessment of Changes in Kidney Allograft Function Using Creatinine-Based Estimates of Glomerular Filtration Rate. American Journal of Transplantation 2007, 7:880-887. 10.1111/j.1600-6143.2006.01690.x, 17391131.
38. Connolly JO, Woolfson RG. A Critique of Clinical Guidelines for Detection of Individuals with Chronic Kidney Disease. Nephron Clinical Practice 2009, 111:c69-c73.
39. Remuzzi G, Benigni A, Remuzzi A. Mechanisms of progression and regression of renal lesions of chronic nephropathies and diabetes. The Journal of Clinical Investigation 2006, 116:288-296. 10.1172/JCI27699, 1359063, 16453013.